CClinicalTrials.gg
Not yet recruitingNCT07698509Updated Jul 13, 2026

Virtual Lifestyle Medicine Group Visits for High Blood Pressure

An interventional study of Lifestyle Medicine Virtual group and Usual Care Group in Hypertension, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to learn whether virtual Lifestyle medicine shared medical appointments (LMSMAs) can help people better manage their blood pressure and improve their overall health.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • high blood pressure
  • Lifestyle medicine shared medical appointments (LMSMAs)
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's planned enrollment of 18 is below the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 880 studies on the registry; 209 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 140 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Current diagnosis of hypertension (ICD codes I10.0-I14.0 billed within the last 5 years Essential HTN, Essential HTN, Primary HTN)
  • Currently receives care at a UTPhysicians; Last seen by a PCP at Victory location within the last 1 year.
  • Able to participate in a virtual format
  • Willingness to participate and engage in home blood pressure monitoring

Exclusion criteria

Exclusion Criteria:

  • Unstable cardiovascular disease (recent Myocardial Infarction (MI), unstable angina, decompensated HF)
  • Advanced Chronic kidney disease (CKD) (eGFR \< 30) without nephrology co-management
  • Active cancer treatment
  • Severe cognitive impairment (unable to engage)
  • Uncontrolled psychiatric illness (e.g., active psychosis)
  • Resistant hypertension (requiring> 3 medications at maximum doses)
  • Unable to participate in English class format
  • Unstable internet or lack of smartphone
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Lifestyle Medicine Virtual Group Visit Program plus usual medical care

    Behavioral: Lifestyle Medicine Virtual group · Behavioral: Usual Care Group

  • Active comparator
    Usual medical care only

    Behavioral: Usual Care Group

Interventions

  • BehavioralLifestyle Medicine Virtual group

    Participants will be given a home BP monitor upon enrollment and the group will engage in twice monthly virtual shared medical appointments (vSMAs) for 4 visits. Prior to each visit, participants will be asked to complete home BP monitoring (twice in the morning and twice in the evening for 3 days before visit), with readings reviewed during visits and medications adjusted as clinically indicated. Participants will complete four sessions over an 8-week period, with one session type offered in each 2 week block.

  • BehavioralUsual Care Group

    Participants will be given a home BP monitor upon enrollment and will be instructed by phone and with an electronic health record (EHR) portal message on proper technique for home BP readings. Participants will continue to have follow-up visits with their PCP as clinically indicated.

06

What researchers measure

Primary outcomes

  1. Change in diastolic blood pressure readings

    Time frame: 2-4 weeks after randomization,6 months after randomization

  2. Change in systolic blood pressure readings

    Time frame: 2-4 weeks after randomization,6 months after randomization

Secondary outcomes

  1. Percentage of eligible participants who agree to participate

    Time frame: end of study (6 months after randomization)

  2. Number of primary care physicians (PCPs) whose patients are included in the program

    Time frame: end of study (6 months after randomization)

  3. Median number of sessions attended by each participant

    Time frame: end of study (6 months after randomization)

  4. Adherence as assessed by the number of of blood pressure (BP) readings submitted between each session

    Time frame: end of study (6 months after randomization)

  5. Adherence to home BP monitoring as assessed by the number of of home BP sessions submitted between each session

    Time frame: end of study (6 months after randomization)

07

Study locations

1 site
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07698509
Lead sponsor
The University of Texas Health Science Center, Houston
Responsible party
Puja Bharat Gandhi (Assistant Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Jul 13, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Jan 3, 2027 (estimated)
Completion
Feb 7, 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Puja B Gandhi, MD, MPH, DipABLM
Contact
Puja.Gandhi@uth.tmc.edu
(713) 500-6714
Natalia Williams
Contact
Natalia.Williams@uth.tmc.edu
(713) 486-3844
Puja B Gandhi, MD, MPH, DipABLM
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion